Is hormone therapy safe after gynecologic cancer?
Key takeaway: Yes, hormone therapy can be safely used by many people with a history of gynecologic cancer, but its safety depends on the type of hormone therapy, cancer type and subtype, and other individual health factors.
Surviving cancer does not mean having to accept the consequences of menopause without support. Options are available, and you deserve access to evidence-informed, personalized care that improves your quality of life and long-term health.
Life after cancer treatment (known as cancer survivorship) can include complex and long-lasting changes that affect physical, mental, and emotional well-being. For young gynecologic cancer survivors who experience surgical menopause, these effects can be profound and occur throughout the body, influencing overall quality of life and long-term health. These experiences should be taken seriously. Your healthcare provider should work with you to understand how menopausal symptoms affect your life. Together, you can identify ways to manage these symptoms that reflect your individual needs and preferences. Hormone therapy can be an important option for improving your overall quality of life and protecting your long-term health. Hormone therapy, also called hormone replacement therapy (HRT), uses hormones (estrogen, with or without progesterone) to manage the symptoms and health effects of menopause.
WHAT ARE THE POTENTIAL BENEFITS OF HORMONE THERAPY?
For people under the age of 45 who experience menopause caused by surgery (known as surgical menopause), hormone therapy can improve quality of life and has other health benefits. Research has linked the early loss of ovarian hormones with increased risk of several long-term health problems, including cardiovascular and bone disease. Some studies also suggest that loss of ovarian hormones may affect longevity1. Hormone therapy can help reduce these risks. Because of these long-term health considerations, it is important to care for women with surgical menopause and determine when hormone therapy can be safely used.
WHAT ARE THE TYPES OF HORMONE THERAPY?
Hormone therapy used to manage menopausal symptoms can be broadly categorized as systemic hormone therapy and local hormone therapy. Systemic hormone therapy circulates throughout the entire body, while local hormone therapy (estrogen) acts primarily in the area where it is applied (most commonly in the vagina).
- Systemic hormone therapy will decrease hot flashes, help sleep disturbance and the other effects of menopause on the whole body.
- Local hormones treat symptoms such as vaginal dryness, bladder irritability/infections, and pain during sex. Very little hormone reaches the bloodstream with local hormone therapy.
Is hormone therapy safe after gynecologic cancer?
For expert advice on your individual experience, talk to your doctor.
There are different safety considerations for local and systemic hormone therapy, and what is appropriate will depend on your cancer history and other individual health factors.
Local hormone therapy
Low-dose vaginal estrogen is used to treat vaginal and urinary symptoms of menopause, including dryness, burning, discomfort, pain during sex, recurrent urinary tract infections, and urinary urgency. It can be safely used by most people with a history of ovarian cancer, endometrial cancer, and other gynecologic cancers2. Local estrogen therapy does not increase the risk of cancer recurrence even in estrogen sensitive cancers because the amount of estrogen absorbed is very low.
Systemic hormone therapy
Systemic hormone therapy requires more individualized consideration. Its potential risks and benefits depend on several factors, including cancer type and subtype, stage, age, and other individual health factors, including cardiovascular health and risk of blood clots. Like other medications, systemic hormone therapy can also cause side effects, which can vary depending on the type and dose. Your healthcare provider can help you understand what side effects to expect based on your individual health factors and the type of hormone therapy being considered.
For people with a history of epithelial ovarian cancer, systemic hormone therapy is considered safe in most cases and has been associated with improved overall survival. However, recommendations vary by ovarian cancer subtype. Systemic hormone therapy should generally be avoided by those with low-grade serous ovarian cancer, while its use following endometrioid ovarian cancer requires more individualized consideration because evidence remains limited3, 4.
For those with a history of endometrial cancer, stage is an important consideration. Available evidence has not shown an increased risk of recurrence with systemic hormone therapy following early-stage endometrial cancer, and systemic hormone therapy may be particularly important to consider for younger women experiencing early menopause. Systemic hormone therapy is generally not recommended following advanced or metastatic endometrial cancer4, 5, 6.
Hormone therapy also raises important questions for those with a history of breast cancer. Given the hereditary links between some breast and ovarian cancers, these questions are particularly relevant for many gynecologic cancer survivors and their families. People with BRCA 1 and BRCA 2 genetic mutations who have not had cancer can safely use hormone therapy after having their ovaries surgically removed to reduce their ovarian cancer risk. Research has shown that hormone use in BRCA carries with early surgical menopause does not increase breast cancer risk7, 8.
While systemic hormone therapy is not generally recommended for breast cancer survivors, low-dose vaginal estrogen is different. Despite widespread misconceptions, large studies have produced reassuring evidence about the safety of low-dose vaginal estrogen in breast cancer survivors, and it can help manage the vaginal and urinary symptoms of menopause9
WHAT ARE OTHER OPTIONS FOR MANAGING MENOPAUSE SYMPTOMS?
If hormone therapy is not an appropriate option for you, there are other non-hormonal options that have been shown to be effective for managing symptoms such as hot flashes and night sweats. Certain medications (venlafaxine, paroxetine, gabapentin, fezolinetant, elinzanetant), cognitive behavioural therapy, and clinical hypnosis are very effective for managing symptoms. Other approaches, such as herbal supplements, acupuncture, yoga, soy products, and dietary modifications have not been consistently proven to improve these symptoms and are not currently recommended as evidence-based treatments10.
The effects of menopause can extend well beyond individual symptoms and can profoundly affect quality of life and long-term health outcomes. If you are experiencing symptoms, speak with your doctor to learn more about which treatment options may be safe and appropriate for you, including hormone therapy. You may consider starting this discussion by asking, “Given my cancer history, what are the risks and benefits of using hormone therapy compared with the risks of experiencing menopause earlier than I otherwise would have?”
References
- Shuster LT, Rhodes DJ, Gostout BS, Grossardt BR, Rocca WA. Premature menopause or early menopause: long-term health consequences. 2010;65(2):161–166.
- Chambers LM, Herrmann A, Michener CM, Ferrando CA, Ricci S. Vaginal estrogen use for genitourinary symptoms in women with a history of uterine, cervical, or ovarian carcinoma. International Journal of Gynecological Cancer. 2020;30(4):515–524.
- Achimaș-Cadariu PA, Păun DL, Pașca A. Impact of hormone replacement therapy on the overall survival and progression free survival of ovarian cancer patients: a systematic review and meta-analysis. Cancers (Basel). 2023;15(2):356.
- Sinno AK, Pinkerton J, Febbraro T, Jones N, Khanna N, Temkin S, Iglesias D, Pothuri B. Hormone therapy (HT) in women with gynecologic cancers and in women at high risk for developing a gynecologic cancer: A Society of Gynecologic Oncology (SGO) clinical practice statement: This practice statement has been endorsed by The North American Menopause Society. Gynecologic Oncology. 2020;157(2):303–306.
- Londero AP, Parisi N, Tassi A, Bertozzi S, Cagnacci A. Hormone replacement therapy in endometrial cancer survivors: a meta-analysis. Journal of Clinical Medicine. 2021;10(14):3165.
- Shim SH, Lee SJ, Kim SN. Effects of hormone replacement therapy on the rate of recurrence in endometrial cancer survivors: a meta-analysis. European Journal of Cancer. 2014;50(9):1628–1637.
- Kotsopoulos, J., Seca, M., Gronwald, J., et al. (2026). Menopausal hormone therapy and the risk of breast cancer in women with a pathogenic variant in BRCA1 or BRCA2. Journal of the National Cancer Institute, 118(5), 856–864.
- Nitschke, A. S., do Valle, H. A., Dawson, L., Kwon, J. S., & Hanley, G. E. (2023). Long-term non-cancer risks in people with BRCA mutations following risk-reducing bilateral salpingo-oophorectomy and the role of hormone replacement therapy: A review. Cancers, 15(3), Article 711.
- McVicker L, Labeit AM, Coupland CA, et al. Vaginal estrogen therapy use and survival in females with breast cancer. JAMA Oncol. 2024;10(1):103–108.
- The North American Menopause Society. The 2023 nonhormone therapy position statement of The North American Menopause Society. 2023;30(6):573–590.